Biowaivers

Biowaivers designate regulatory exemptions from bioequivalence studies for oral solid dosage forms based on demonstration that the drug substance is highly soluble and highly permeable with rapidly dissolving formulations according to the Biopharmaceutics Classification System, eliminating the need for in vivo pharmacokinetic studies in certain development and approval contexts.

The pharmaceutical industry leverages biowaivers to reduce development costs and timelines for generic drugs and additional strengths of approved products that qualify under BCS-based criteria. BCS Class I drugs with high solubility and high permeability qualify most readily for biowaivers when formulations dissolve rapidly under standardised conditions. BCS Class III drugs with high solubility and low permeability may qualify for biowaivers when formulations are very rapidly dissolving and the drug product is qualitatively and quantitatively similar. FDA and EMA guidance specify requirements. Dissolution testing criteria must demonstrate rapid complete dissolution across physiological pH values. As generic drug development continues and regulatory science evolves, biowaiver criteria continue expanding based on accumulated evidence supporting in vitro-in vivo correlation.